HER2 positive biliary tract cancer – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Wed, 17 Jun 2026 04:02:42 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png HER2 positive biliary tract cancer – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Trastuzumab Deruxtecan and Rilvegostomig for Patients with Advanced HER2-positive Biliary Tract Cancer https://clinicaltrials.eu/trial/study-of-trastuzumab-deruxtecan-and-rilvegostomig-for-patients-with-advanced-her2-positive-biliary-tract-cancer/ Wed, 29 Apr 2026 15:05:01 +0000 https://clinicaltrials.eu/trial/study-of-trastuzumab-deruxtecan-and-rilvegostomig-for-patients-with-advanced-her2-positive-biliary-tract-cancer/ This clinical trial is focused on studying a type of cancer known as HER2-expressing Biliary Tract Cancer, which affects the bile ducts. The study will compare the effectiveness of a new treatment combination against the current standard treatment. The new treatment involves two medications: Trastuzumab Deruxtecan (also known as DS-8201a) and Rilvegostomig (also known as AZD2936). Trastuzumab Deruxtecan is a type of medication called an antibody-drug conjugate, which is designed to target and kill cancer cells. Rilvegostomig is a bispecific monoclonal antibody that targets specific proteins involved in cancer growth. The standard treatment being compared includes the medications Gemcitabine, Cisplatin, and Durvalumab.

The purpose of this study is to see if the new treatment combination can improve the overall survival of patients with this type of cancer compared to the standard treatment. Participants in the study will be randomly assigned to receive either the new treatment or the standard treatment. The study will monitor the participants over time to assess the effectiveness and safety of the treatments. The study will also look at other factors such as how long the treatments can keep the cancer from getting worse and the overall response of the cancer to the treatments.

This study is important because it aims to find better treatment options for patients with advanced biliary tract cancer, which is a challenging condition to treat. By participating in this study, researchers hope to gather valuable information that could lead to improved outcomes for patients in the future. The study is expected to continue for several years to ensure comprehensive data collection and analysis.

]]>